Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological effects of hedgehog inhibitors in basal cell carcinoma
2020-001309-22Phase 4Completed
- Sponsor
- IQVIA
- Start
- Dec 2020
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sonidegib and vismodegib in basal cell carcinoma (BCC) and superficial basal cell carcinoma (BCC) (2 arms), sponsored by IQVIA. Primary endpoint: Tumor-infiltrating T cells. Started Dec 2020; status: completed.
02
Drugs
sonidegibvismodegib
03
Conditions
basal cell carcinoma (BCC)superficial basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2020-001309-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001309-22.